ImmunoGen

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody. The small-molecule drugs are highly potent cell-killing (cytotoxic) agents, while the monoclonal antibodies identify and bind to tumor cells. An important characteristic of TAPs is that they remain inactive and nontoxic until they bind to the surface of a tumor cell, after which their full cytotoxicity is restored.

Contact Details: 128 Sidney Street Cambridge MA 02139 United States of America Tel: (617) 995-2500 Fax: 617-995-2510 Email: WWW: www.immunogen.com/

Loading...

Recent Publications by ImmunoGen:
Antibody-cytotoxic agent conjugates: preparation and characterization. Conjugates of antibodies with cytotoxic agents offer a targeted...	23rd April, 2009	ImmunoGen Inc., Waltham, MA, USA.	Methods Mol Biol. 2009;525:445-67, xiv. DOI Direct Link
Targeted cancer therapy: conferring specificity to cytotoxic drugs. The therapeutic activity of most anticancer drugs in clinical use is...	29th May, 2008	ImmunoGen, Inc., 128 Sidney Street, Cambridge, Massachusetts 02139, USA.	Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18. DOI Direct Link
Cell killing by antibody-drug conjugates. Antibody-drug conjugates (ADCs) are designed to specifically bind to and...	10th November, 2007	ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA.	Cancer Lett. 2007 Oct 8;255(2):232-40. Epub 2007 Jun 5. DOI Direct Link
The rabies peripheral challenge test: more accurate determination of vaccine potency. The National Institutes of Health (NIH) rabies vaccine potency test is...	5th January, 2007	ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA.	Vaccine. 2006 Nov 30;24(49-50):7115-23. Epub 2006 Jul 21. DOI Direct Link
Semisynthetic maytansine analogues for the targeted treatment of cancer. Maytansine, a highly cytotoxic natural product, failed as an anticancer...	12th September, 2006	ImmunoGen, Inc., 128 Sidney Street, Cambridge, Massachusetts 02139, USA.	J Med Chem. 2006 Jul 13;49(14):4392-408. DOI Direct Link
→View more ImmunoGen research publications.

Press Releases on ImmunoGen:
MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development	23rd January, 2009	MedPredict	SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing
Bioinvent's Candidate Drug Against Hiv/Aids Approved To Enter Clinical	1st May, 2005	Bioinvent	Bioinvent's Candidate Drug Against Hiv/Aids Approved To Enter Clinical
MorphoSys Reports third quarter 2004 results. Company expects to obtain	1st September, 2004	Morphosys	MorphoSys Reports third quarter
BioInvent Interim Report 1 January-30 June 2005	1st December, 2002	Bioinvent	BioInvent Interim Report 1 January-30 June 2005
Aventis To Develop Antibodies With ImmunoGen	1st June, 2002	Biotracker	Aventis To Develop Antibodies With

BioNews Results for ImmunoGen:
Intercell Supports the Japanese Encephalitis Vaccination Recommendations of CDC's Advisory Committee on Immuni	Pharma Live:  Jun 28 2009 10:23PM Matching: immunogen
Cancer Vaccines - New cancer vaccines study results reported from J.Y. Yu et al	NewsRX:  Jun 27 2009 4:33PM Matching: immunogen
ImmunoGen, Inc. Announces Completion of Public Offering of Common Stock	Pharma Live:  Jun 26 2009 9:58AM Matching: immunogen
Pharmaceuticals' mergers, cutbacks bring subleases in suburbs	Mass High Tech:  Jun 26 2009 4:29AM Matching: immunogen
ICGEB transfers technology for development of malaria vaccine 'Jaivac' to Bharat Biotech	PharmaBiz:  Jun 26 2009 3:12AM Matching: immunogen
Promote your company here: BioNewsCast - Press Release Distribution	→View more ImmunoGen news.

ImmunoGen Patents:
US Patent No.	Title
6333410	Process for the preparation and purification of thiol-containing maytansinoids
6913748	Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
7008942	Cytotoxic agents comprising taxanes and their therapeutic use
7049316	Prodrugs of CC-1065 analogs
7078175	Antibodies for apoptosis EI24 protein and methods of use
→View more ImmunoGen patents.

ImmunoGen (IMGN) Financial information Links from Barchart
IMGN Quote from from Barchart.com
IMGN Chart from from Barchart.com
IMGN Profile from from Barchart.com
IMGN Opinion from from Barchart.com
→View more ImmunoGen finance information.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 18 individuals from ImmunoGen using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 373 times since April 2007, the link to the organisation's website has been followed 65 times

Recent Search Terms used to find this page: immunogen e-mail address | vaccine companies in ma usa | linking cytotoxic agents to monoclonal antibodies service contracts | immunogen email contact | maytansine solubility | immunogen contact | immunogen patents | immunogen | immunogen | immunogen email contact | .

Search for more companies in Cambridge

Search for more companies in MA

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ImmunoGen